Aarti Drugs surges on robust Q4 earnings
Q4 profit up 86% at Rs 13.81 crore against Rs 7.41 crore in year ago quarter.
Aarti Drugs is locked in upper circuit of 10% at Rs 210 on NSE after reporting a robust 86% year-on-year (y-o-y) jump in net profit at Rs 13.81 crore for the fourth quarter ended March 31, 2013.
The pharmaceutical company had reported a profit of Rs 7.41 crore in the year ago quarter. Net sales grew 10.6% at Rs 220 crore on y-o-y basis.
For the full financial year 2012-13, net profit more-than-doubled to Rs 45.24 crore against profit of Rs 22.46 crore in FY2011-12. Net sales surged 25% at Rs 826 crore from Rs 662 crore in previous year.
Meanwhile, the board has recommended a final dividend of Rs 4 per share on equity shares of Rs 10 each.
The stock opened at Rs 202 and has seen a combined 14,537 shares changing hands on the counter so far. There are pending buy orders for 9,683 shares on NSE and BSE at 0945 hours.
The pharmaceutical company had reported a profit of Rs 7.41 crore in the year ago quarter. Net sales grew 10.6% at Rs 220 crore on y-o-y basis.
For the full financial year 2012-13, net profit more-than-doubled to Rs 45.24 crore against profit of Rs 22.46 crore in FY2011-12. Net sales surged 25% at Rs 826 crore from Rs 662 crore in previous year.
Meanwhile, the board has recommended a final dividend of Rs 4 per share on equity shares of Rs 10 each.
The stock opened at Rs 202 and has seen a combined 14,537 shares changing hands on the counter so far. There are pending buy orders for 9,683 shares on NSE and BSE at 0945 hours.